Skip to main content
Fig. 2 | AIDS Research and Therapy

Fig. 2

From: An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1

Fig. 2

a Efficacy and b safety results of the indirect treatment comparisons at Week 144. Comparisons assumed TDF/FTC and TAF/FTC to be equivalent. Horizontal lines represent 95% CI. ABC, abacavir; BIC, bictegravir; DTG, dolutegravir; FDA, US Food and Drug Administration; FTC, emtricitabine; TAF, tenofovir alafenamide; 3TC, lamivudine. aComparison against DTG/ABC/3TC could not be estimated due to zero events in one treatment group. bFewer SAEs occurred with DTG + 3TC than with BIC/FTC/TAF (P = 0.014) and DTG/ABC/3TC (P = 0.006)

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us